• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Does Lactin-V Treatment Reduce the Recurrence of Bacterial Vaginosis?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Bacterial vaginosis (BV) is common with a high risk for recurrence
  • Lactin-V
    • Treatment containing live L. crispatus, a naturally occurring vaginal strain of bacteria
    • Used following metronidazole to encourage vaginal colonization with L. crispatus
  • Cohen et al. (NEJM, 2020) conducted a phase 2b trial to assess whether treatment with Lactin-V after metronidazole would result in a significantly lower incidence of recurrence of BV

METHODS:

  • Randomized, double-blind, placebo-controlled, phase 2b trial (RCT) 
  • Participants
    • Women 18 to 45 years of age with BV
    • Completed course of vaginal metronidazole gel (5-day course)
  • Interventions (within 48 hours of completing metronidazole treatment)
    • Vaginally administered Lactin-V for 11 weeks (Lactin-V at 2×109 CFU per dose; carton containing 25 vaginal applicators)
    • Placebo (same inactive ingredients but without live L. crispatus)
  • Study design
    • Participants were randomly assigned 2:1 to Lactin-V or placebo
    • Follow up was through week 24
    • Analysis was in intention-to-treat
  • Statistical analysis
    • 228 participants required
    • 70% power to detect by week 12 a 50% lower recurrence of BV in the Lactin-V group vs the placebo group
  • Primary outcome
    • Percentage of women who had a recurrence of bacterial vaginosis by week 12

RESULTS:

  • 228 women were randomized
    • Lactin-V: 152 women
    • Placebo: 76 women
  • By week 12 (primary outcome): BV recurrence was significantly lower in the Lactin-V group
    • Lactin-V: 30% (46 participants)
    • Placebo: 45% (34 participants)
    • Risk ratio (RR): 0.66 (95% CI, 0.44 to 0.87; P=0.01)
  • By week 24 (secondary outcome):
    • RR: 0.73 (95% CI,  0.54 to 0.92)
  • At the 12-week visit, L. crispatus detected in 79% of participants in the Lactin-V group
  • Safety
    • No significant difference in the prevalence of adverse events between the two groups, including local vs systemic effects
    • No severe events were associated with treatment or placebo group

CONCLUSION:

  • The use of Lactin-V following a 5-day course of metronidazole was associated with a significantly lower incidence of recurrent BV at 12 weeks, compared to placebo with sustained effect through 24 weeks
  • Further studies required to determine long-term effectiveness beyond 12 and 24 weeks
  • The authors state

These results extend earlier findings seen with Lactin-V and support the general safety of the current formulation and dosing strategy 

Learn More – Primary Sources:

Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Bacterial Vaginosis – CDC Diagnosis and Treatment Recommendations
Practical info for your gynecology practice
Diagnosing Vaginitis – Why the Office Visit Still Matters
Are Probiotics Useful for the Treatment of Vulvovaginal Candidiasis?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site